Mr. Stephen Van Deventer reports

PREVECEUTICAL ENTERS INTO LOAN AGREEMENTS

Preveceutical Medical Inc. has entered into a series of unsecured, non-convertible and interest-free loan agreements with the company's chief executive officer, interim chief financial officer and chair, Stephen Van Deventer, and the company's former president and director, Kimberly Van Deventer, in the aggregate amount of $297,731.

The proceeds of the loans are intended to be used for working capital purposes.

Mr. Van Deventer's participation is considered to be a related-party transaction as defined under Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). The company has relied on the exemption from the minority shareholder approval requirement of MI 61-101 contained in Section 5.7(1)(f) of MI 61-101 in respect of such insider participation.

About Preveceutical Medical Inc.

Preveceutical is a health science company focused on developing innovative options for preventive and curative therapies, utilizing organic and nature identical products. The company aims to be a leader in the preventive health science sector.

With the completion of three of its research programs, the company is actively working on the development, clinical trials and commercialization of its products, and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

We seek Safe Harbor.